北京大学学报（医学版） ›› 2023, Vol. 55 ›› Issue (5): 775-780. doi: 10.19723/j.issn.1671-167X.2023.05.002
前列腺癌新辅助治疗与辅助治疗的现状及进展
薛蔚*(
),董樑,钱宏阳,费笑晨
- 上海交通大学医学院附属仁济医院泌尿外科, 上海 200127
蔚 薛*(),樑 董,宏阳 钱,笑晨 费
中图分类号:
- R737.25
| 1 |
ChenR , RenS , Chinese Prostate Cancer Consortium ,et al.Prostate cancer in Asia: A collaborative report[J].Asian J Urol,2014,1(1):15-29.
doi: 10.1016/j.ajur.2014.08.007 |
| 2 |
ManoR , EasthamJ , YossepowitchO .The very-high-risk prostate cancer: A contemporary update[J].Prostate Cancer Prostatic Dis,2016,19(4):340-348.
doi: 10.1038/pcan.2016.40 |
| 3 |
ShelleyMD , KumarS , WiltT ,et al.A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma[J].Cancer Treat Rev,2009,35(1):9-17.
doi: 10.1016/j.ctrv.2008.08.002 |
| 4 | KumarS , ShelleyM , HarrisonC ,et al.Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer[J].Cochrane Database Syst Rev,2006,(4):CD006019. |
| 5 |
O'DonnellA , JudsonI , DowsettM ,et al.Hormonal impact of the 17alpha-hydroxylase/C(17, 20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer[J].Br J Cancer,2004,90(12):2317-2325.
doi: 10.1038/sj.bjc.6601879 |
| 6 |
TaplinME , MontgomeryB , LogothetisCJ ,et al.Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: Results of a randomized phase Ⅱ neoadjuvant study[J].J Clin Oncol,2014,32(33):3705-3715.
doi: 10.1200/JCO.2013.53.4578 |
| 7 |
EfstathiouE , DavisJW , PistersL ,et al.Clinical and biological characterisation of localised high-risk prostate cancer: Results of a randomised preoperative study of a luteinising hormone-releasing hormone agonist with or without abiraterone acetate plus prednisone[J].Eur Urol,2019,76(4):418-424.
doi: 10.1016/j.eururo.2019.05.010 |
| 8 |
MontgomeryB , TretiakovaMS , JoshuaAM ,et al.Neoadjuvant enzalutamide prior to prostatectomy[J].Clin Cancer Res,2017,23(9):2169-2176.
doi: 10.1158/1078-0432.CCR-16-1357 |
| 9 |
YangX , AllenJC , AslimEJ ,et al.Patient-reported outcomes of a phase Ⅱ neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial[J].Int J Urol,2022,29(11):1322-1330.
doi: 10.1111/iju.14994 |
| 10 |
DevosG , ToscoL , BaldewijnsM ,et al.ARNEO: A randomized phase Ⅱ trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer[J].Eur Urol,2023,83(6):508-518.
doi: 10.1016/j.eururo.2022.09.009 |
| 11 |
MckayRR , YeH , XieW ,et al.Evaluation of intense androgen deprivation before prostatectomy: A randomized phase Ⅱ trial of enzalutamide and leuprolide with or without abiraterone[J].J Clin Oncol,2019,37(11):923-931.
doi: 10.1200/JCO.18.01777 |
| 12 |
EfstathiouE , BoukovalaM , SpetsierisN ,et al.Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC)[J].J Clin Oncol,2020,38,5504.
doi: 10.1200/JCO.2020.38.15_suppl.5504 |
| 13 |
MckayRR , XieW , YeH ,et al.Results of a randomized phase Ⅱ trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer[J].J Urol,2021,206(1):80-87.
doi: 10.1097/JU.0000000000001702 |
| 14 |
SweeneyCJ , ChenYH , CarducciM ,et al.Chemohormonal therapy in metastatic hormone-sensitive prostate cancer[J].N Engl J Med,2015,373(8):737-746.
doi: 10.1056/NEJMoa1503747 |
| 15 |
JamesND , SydesMR , ClarkeNW ,et al.Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial[J].Lancet,2016,387(10024):1163-1177.
doi: 10.1016/S0140-6736(15)01037-5 |
| 16 |
PanJ , ChiC , QianH ,et al.Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study[J].Urol Oncol,2019,37(12):991-998.
doi: 10.1016/j.urolonc.2019.07.009 |
| 17 |
DreicerR , Magi-GalluzziC , ZhouM ,et al.Phase Ⅱ trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate can-cer[J].Urology,2004,63(6):1138-1142.
doi: 10.1016/j.urology.2004.01.040 |
| 18 | MikkilineniN , HyamsES .Neoadjuvant therapies for surgical management of high-risk, localized prostate cancer[J].Transl Cancer Res,2018,7(Suppl 6):S662-S675. |
| 19 |
FizaziK , FaivreL , LesaunierF ,et al.Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): A phase 3 randomised controlled trial[J].Lancet Oncol,2015,16(7):787-794.
doi: 10.1016/S1470-2045(15)00011-X |
| 20 |
潘家骅, 刘家舟, 王勇,等.新辅助内分泌治疗联合化疗对极高危局部进展期前列腺癌疗效的多中心临床分析[J].中华泌尿外科杂志,2021,42(9):685-690.
doi: 10.3760/cma.j.cn112330-20210819-00436 |
| 21 |
GlicksmanR , SanmamedN , ThomsJ ,et al.A phase 1 pilot study of preoperative radiation therapy for prostate cancer: Long-term toxicity and oncologic outcomes[J].Int J Radiat Oncol Biol Phys,2019,104(1):61-66.
doi: 10.1016/j.ijrobp.2018.12.054 |
| 22 |
SartorO , de BonoJ , ChiKN ,et al.Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer[J].N Engl J Med,2021,385(12):1091-1103.
doi: 10.1056/NEJMoa2107322 |
| 23 |
GolanS , FrumerM , ZoharY ,et al.Neoadjuvant 177Lu-PSMA-I&T radionuclide treatment in patients with high-risk prostate cancer before radical prostatectomy: A single-arm phase 1 trial[J].Eur Urol Oncol,2023,6(2):151-159.
doi: 10.1016/j.euo.2022.09.002 |
| 24 | HanksGE .External-beam radiation therapy for clinically localized prostate cancer: Patterns of care studies in the United States[J].NCI Monogr,1988,(7):75-84. |
| 25 |
AusG , NordenskjoldK , RobinsonD ,et al.Prognostic factors and survival in node-positive (N1) prostate cancer: A prospective study based on data from a Swedish population-based cohort[J].Eur Urol,2003,43(6):627-631.
doi: 10.1016/S0302-2838(03)00156-8 |
| 26 |
PassoniNM , FajkovicH , XylinasE ,et al.Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: Value of extranodal extension and size of the largest LN metastasis[J].BJU Int,2014,114(4):503-510.
doi: 10.1111/bju.12342 |
| 27 | DaneshmandS , QuekML , SteinJP ,et al.Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: Long-term results[J].J Urol,2004,172(6 Pt 1):2252-2255. |
| 28 |
WiegelT , BartkowiakD , BottkeD ,et al.Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial[J].Eur Urol,2014,66(2):243-250.
doi: 10.1016/j.eururo.2014.03.011 |
| 29 |
ThompsonIM , TangenCM , ParadeloJ ,et al.Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial[J].J Urol,2009,181(3):956-962.
doi: 10.1016/j.juro.2008.11.032 |
| 30 |
BollaM , van PoppelH , TombalB ,et al.Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911)[J].Lancet,2012,380(9858):2018-2027.
doi: 10.1016/S0140-6736(12)61253-7 |
| 31 |
HackmanG , TaariK , TammelaTL ,et al.Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension[J].Eur Urol,2019,76(5):586-595.
doi: 10.1016/j.eururo.2019.07.001 |
| 32 |
GhavamianR , BergstralhEJ , BluteML ,et al.Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: A matched comparison[J].J Urol,1999,161(4):1223-1227.
doi: 10.1016/S0022-5347(01)61640-9 |
| 33 |
MessingEM , ManolaJ , YaoJ ,et al.Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy[J].Lancet Oncol,2006,7(6):472-479.
doi: 10.1016/S1470-2045(06)70700-8 |
| 34 |
AbdollahF , KarnesRJ , SuardiN ,et al.Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer[J].J Clin Oncol,2014,32(35):3939-3947.
doi: 10.1200/JCO.2013.54.7893 |
| 35 |
LowranceW , DreicerR , JarrardDF ,et al.Updates to advanced prostate cancer: AUA/SUO guideline (2023)[J].J Urol,2023,209(6):1082-1090.
doi: 10.1097/JU.0000000000003452 |
| 36 |
RoachPJ , FrancisR , EmmettL ,et al.The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: Results of an Australian prospective multicenter study[J].J Nucl Med,2018,59(1):82-88.
doi: 10.2967/jnumed.117.197160 |
| 37 |
YaxleyJW , RaveenthiranS , NouhaudF X ,et al.Risk of metastatic disease on 68gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1 253 men at the diagnosis of prostate cancer[J].BJU Int,2019,124(3):401-407.
doi: 10.1111/bju.14828 |
| 38 |
HofmanMS , LawrentschukN , FrancisRJ ,et al.Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study[J].Lancet,2020,395(10231):1208-1216.
doi: 10.1016/S0140-6736(20)30314-7 |
| [1] | 高加勒, 张忠涛. 局部进展期直肠癌精准治疗现状与展望[J]. 北京大学学报（医学版）, 2026, 58(2): 247-250. |
| [2] | 李伟浩, 张学民, 李伟, 张韬, 张小明. 胸主动脉腔内修复术左肱动脉穿刺点使用血管缝合器处理的临床效果[J]. 北京大学学报（医学版）, 2026, 58(2): 388-392. |
| [3] | 李嘉临, 陈力侨, 唐家天, 吴艳, 王安强. 胃肝样腺癌转化治疗1例[J]. 北京大学学报（医学版）, 2026, 58(2): 399-404. |
| [4] | FarinEbrahimi, 冯志强, FarazEbrahimi, 韩玮华, 于子杨, 贾宽宽, 安金刚. 上颌药物相关性颌骨坏死的不同分期手术治疗效果[J]. 北京大学学报（医学版）, 2026, 58(1): 107-114. |
| [5] | 潘莲菲, 李文静, 王瑞洋, 焦剑, 曹战强, 高丽, 释栋. 口服抗生素辅助牙周机械治疗对重度牙周炎的短期疗效及影响因素[J]. 北京大学学报（医学版）, 2026, 58(1): 30-36. |
| [6] | 刘艳华, 陆敏, 赵旭阳, 张宽根, 武睿, 梅放, 戴志豪, 由江峰, 裴斐. 肿瘤转移抑制基因LASS2去磷酸化对液泡型ATP酶活性及前列腺癌侵袭性的影响[J]. 北京大学学报（医学版）, 2025, 57(6): 1113-1123. |
| [7] | 杨小勇, 张帆, 马潞林, 刘承. 前列腺导管腺癌临床特征及腺外侵犯的影响因素[J]. 北京大学学报（医学版）, 2025, 57(5): 956-960. |
| [8] | 宁家昕, 王浩然, 罗书航, 敬吉波, 王建业, 侯惠民, 刘明. 氧化应激相关基因与前列腺癌关系的多组学分析[J]. 北京大学学报（医学版）, 2025, 57(4): 633-643. |
| [9] | 王泽远, 于栓宝, 郑浩轲, 陶金, 范雅峰, 张雪培. 基于临床特征和多参数MRI的前列腺癌盆腔淋巴结转移的术前预测模型[J]. 北京大学学报（医学版）, 2025, 57(4): 684-691. |
| [10] | 康一帆, 葛严军, 吕晓鸣, 谢尚, 单小峰, 蔡志刚. 即刻种植体支持式义齿修复的血管化髂骨瓣重建下颌骨缺损[J]. 北京大学学报（医学版）, 2025, 57(1): 78-84. |
| [11] | 李志存, 吴天俣, 梁磊, 范宇, 孟一森, 张骞. 穿刺活检单针阳性前列腺癌术后病理升级的危险因素分析及列线图模型构建[J]. 北京大学学报（医学版）, 2024, 56(5): 896-901. |
| [12] | 田宇轩,阮明健,刘毅,李德润,吴静云,沈棋,范宇,金杰. 双参数MRI改良PI-RADS评分4分和5分病灶的最大径对临床有意义前列腺癌的预测效果[J]. 北京大学学报（医学版）, 2024, 56(4): 567-574. |
| [13] | 姚凯烽,阮明健,李德润,田宇轩,陈宇珂,范宇,刘毅. 靶向穿刺联合区域系统穿刺对PI-RADS 4~5分患者的前列腺癌诊断效能[J]. 北京大学学报（医学版）, 2024, 56(4): 575-581. |
| [14] | 欧俊永,倪坤明,马潞林,王国良,颜野,杨斌,李庚午,宋昊东,陆敏,叶剑飞,张树栋. 肌层浸润性膀胱癌合并中高危前列腺癌患者的预后因素[J]. 北京大学学报（医学版）, 2024, 56(4): 582-588. |
| [15] | 李文菁,张保宙,李恒,赖良鹏,杜辉,孙宁,龚晓峰,李莹,王岩,武勇. 胫距跟融合治疗终末期踝和后足病变的中短期临床结果[J]. 北京大学学报（医学版）, 2024, 56(2): 299-306. |
|
||
